Beta Bionics (NASDAQ:BBNX) Stock: Insider Stephen Feider Sells 744 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 744 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $17.00, for a total transaction of $12,648.00. Following the sale, the chief financial officer owned 159,378 shares in the company, valued at $2,709,426. This trade represents a 0.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Stephen Feider also recently made the following trade(s):

• On Thursday, November 5th, Stephen Feider sold 382 shares of Beta Bionics stock. The shares were sold at an average price of $17.04, for a total transaction of $6,509.28.
• On Wednesday, September 2nd, Stephen Feider sold 6,675 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $127,559.25.

Beta Bionics Price Performance

Shares of Beta Bionics stock traded down $0.09 on Friday, hitting $16.42. The company had a trading volume of 1,095,375 shares, compared to its average volume of 1,171,084. The stock has a 50-day moving average of $18.47 and a 200-day moving average of $14.86. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The firm has a market capitalization of $892.76 million, a P/E ratio of -8.92 and a beta of 3.44.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.01. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. The business had revenue of $35.51 million for the quarter. Equities analysts predict that Beta Bionics, Inc. will post -2.04 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. 49 Wealth Management LLC acquired a new position in shares of Beta Bionics during the 3rd quarter worth approximately $260,000. Ieq Capital LLC boosted its holdings in shares of Beta Bionics by 33.9% in the 3rd quarter. Ieq Capital LLC now owns 19,550 shares of the company’s stock valued at $371,000 after buying an additional 4,953 shares during the last quarter. Lisanti Capital Growth LLC acquired a new position in Beta Bionics during the third quarter worth $683,000. Jefferies Financial Group Inc. acquired a new position in Beta Bionics during the third quarter worth $1,708,000. Finally, Commonwealth Equity Services LLC increased its holdings in Beta Bionics by 34.7% during the third quarter. Commonwealth Equity Services LLC now owns 31,795 shares of the company’s stock worth $603,000 after buying an additional 8,196 shares during the last quarter.

Analyst Ratings Changes

Several analysts have issued reports on the company. Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 31st. UBS Group restated a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a report on Tuesday, September 15th. Truist Financial upped their price objective on Beta Bionics from $23.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday, September 24th. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, Robert W. Baird lifted their target price on Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $23.69.

Beta Bionics Company Profile

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.